Recce Pharmaceuticals Ltd. (RCE) Price & Analysis

Compare

21 Followers

RCE Stock Chart & Stats

AU$0.41

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.41

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.28 - AU$0.73

Previous CloseN/A

Volume21.12K

Average Volume (3M)154.69K

Market Cap

AU$133.02M

Enterprise ValueAU$143.92M

Total Cash (Recent Filing)AU$602.99K

Total Debt (Recent Filing)AU$11.26M

Price to Earnings (P/E)―

Beta0.97

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding289,183,400

10 Day Avg. Volume112,630

30 Day Avg. Volume154,688

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)-22.52

Price to Sales (P/S)9.15

P/FCF Ratio-3.36

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Platform-focused R&D / PipelineRecce's platform-focused model, centered on its synthetic polymer anti-infective platform and lead candidate RECCE 327, concentrates R&D on multiple related programs. This platform approach can create scalable value across indications and aligns long-term clinical/regulatory upside with concentrated development spend.

Free Cash Flow ImprovementA reported 51.97% free cash flow growth indicates improving cash generation ability despite ongoing losses. If sustained, stronger free cash flow can extend the clinical development runway, reduce near-term external financing needs, and support continued progression of trials — a durable operational improvement.

Operational Efficiency (ROE)Positive ROE of 7.02% implies the company has been able to generate some returns from its equity base despite balance-sheet strain. This suggests managerial ability to deploy capital efficiently in R&D activities, which is a structural strength if capital allocation discipline and execution continue.

Bears Say

Declining RevenueA 21.73% revenue decline signals weakening top-line traction. For a clinical-stage biotech, falling revenue constrains the ability to self-fund trials, increases dependence on external capital, reduces scale benefits and bargaining power, and materially limits strategic flexibility over the coming months.

Severe Negative Profitability / MarginsNet margin of -285.37% and EBIT margin of -271.76% reflect severe unprofitability, with losses dwarfing revenues. Such structural deficits necessitate material capital injections or successful clinical outcomes to correct, heightening dilution and solvency risks while limiting reinvestment capacity.

Balance-sheet Weakness / Negative EquityDebt-to-equity of -3.53 and negative equity indicate elevated leverage and balance-sheet fragility. This raises refinancing and covenant risks, constrains options for strategic partnerships or acquisitions, and makes sustaining multi-period development programs highly reliant on external funding.

Recce Pharmaceuticals Ltd. News

Recce Pharmaceuticals Deepens R&D-Driven Loss as Anti-Infective Programs Advance

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) just unveiled an announcement. Recce Pharmaceuticals reported a widened half-year loss of...

10d ago

Recce Pharmaceuticals Director Options Lapse Following Scheduled Expiry

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has provided an update. Recce Pharmaceuticals reported a change in the securities...

13d ago

Recce Pharmaceuticals Options Lapse, Simplifying Capital Structure

An announcement from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) is now available. Recce Pharmaceuticals has announced the cessation...

13d ago

Recce Pharmaceuticals Deepens U.S. Army Ties With New Burn Wound Gel Study

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has provided an update. Recce Pharmaceuticals has signed a new Cooperative Research...

1M ago

Recce Advances Phase 3 Diabetic Foot Trial and Strengthens Anti-Infective Pipeline

An announcement from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) is now available. Recce Pharmaceuticals reported significant operational progress...

1M ago

Recce Pharmaceuticals Secures $5.3m R&D Rebate to Bolster Anti-Infective Pipeline

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has issued an announcement. Recce Pharmaceuticals has received an AUD $5.34 million...

2M ago

Recce Pharmaceuticals Secures A$85 Million R&D Tax Incentive for Global Anti-Infective Programs

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has shared an update. Recce Pharmaceuticals has been awarded an Advanced Overseas...

3M ago

Recce Pharmaceuticals Secures Hong Kong Patent for Anti-Infectives

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has provided an update. Recce Pharmaceuticals Ltd. announced the granting of a...

3M ago

Recce Pharmaceuticals Reports Promising Preclinical Results for Inhaled RECCE® 327

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has issued an announcement. Recce Pharmaceuticals Ltd. announced positive preclinical results for...

3M ago

Recce Pharmaceuticals Mourns the Loss of Founder Dr. Graham JH Melrose

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has shared an announcement. Recce Pharmaceuticals Ltd. announced the passing of its...

4M ago

RCE FAQ

What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?

Recce Pharmaceuticals Ltd. lowest share price was AU$0.28 and its highest was AU$0.73 in the past 12 months.

What is Recce Pharmaceuticals Ltd.’s market cap?

Recce Pharmaceuticals Ltd.’s market cap is AU$133.02M.

When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Recce Pharmaceuticals Ltd.’s earnings last quarter?

Currently, no data Available

Is Recce Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Recce Pharmaceuticals Ltd. pay dividends?

Recce Pharmaceuticals Ltd. does not currently pay dividends.

What is Recce Pharmaceuticals Ltd.’s EPS estimate?

Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Recce Pharmaceuticals Ltd. have?

Recce Pharmaceuticals Ltd. has 289,183,400 shares outstanding.

What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:RCE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Recce Pharmaceuticals Ltd. Stock Smart Score

Neutral

Blogger Sentiment

Bullish

AU:RCE Sentiment 70%
Sector Average ―

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

94.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Recce Pharmaceuticals Ltd.

Recce Pharmaceuticals Ltd. (RCE) is a biotechnology company focused on the development and commercialization of innovative anti-infective therapies. The company specializes in creating synthetic polymers to combat serious infections, particularly those caused by antibiotic-resistant bacteria. Recce's lead product candidate, RECCE 327, is designed to treat a range of infections, including sepsis, and is positioned to address the growing global health challenge of antibiotic resistance.